Serum-Free Stem Cell Culture for Controlled Osteochondral Tissue Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-based advanced therapy medicinal products (ATMPs) for bone regenerative strategies face challenges such as uncontrolled tissue formation, lack of integration with host tissue, unknown mechanisms of action, and side effects due to high doses of bone morphogenetic proteins (BMPs), limiting their clinical translation and effectiveness in treating bone, cartilage, and joint disorders.
Innovation Solution
A method involving the culture of mesenchymal stem cells in serum-free medium without BMP, followed by BMP supplementation, and subsequent seeding on biocompatible carriers, using a chemically defined medium that includes specific growth factors like BMP2, BMP6, TGFβ, and GDF5 to enhance osteochondrogenic differentiation and aggregation, promoting controlled tissue formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fetal bovine serum (FBS) is used in cell culture media to promote cell proliferation, then cell growth is enhanced, but the variability of serum leads to uncontrolled experimental outcomes and interferes with BMP effects
Solution Approach 1:
The patent changes the chemical composition parameters of the culture media by replacing serum-based media with a chemically defined serum-free media containing specific growth factors (BMP-2, BMP-4, BMP-6, BMP-7, IGF-1, TGF-β1, insulin, transferrin, selenium, L-ascorbic acid). This parameter change eliminates the variability inherent in serum while maintaining cell proliferation capabilities through controlled addition of essential growth factors.
Solution Approach 2:
The patent extracts and removes the fetal bovine serum component from the culture media, eliminating the source of variability and interference with BMP effects. The essential proliferative and differentiative functions previously provided by serum are replaced by a defined combination of specific growth factors and nutrients, allowing for controlled and reproducible experimental outcomes.
2Productivity
If high doses of BMPs are used to promote bone formation, then osteogenic differentiation is enhanced, but side effects occur that limit clinical translation
Solution Approach 1:
The patent changes the dosage parameters of BMPs by using lower, more physiological concentrations (e.g., 50-200 ng/mL for BMP-2, BMP-4, BMP-6, BMP-7) combined with a synergistic cocktail of additional growth factors including IGF-1 (10-100 ng/mL), TGF-β1 (1-10 ng/mL), insulin (10-100 μg/mL), and L-ascorbic acid (50-200 μg/mL). This parameter optimization achieves effective osteogenic differentiation while reducing the harmful side effects associated with high-dose BMP monotherapy.
Solution Approach 2:
The patent employs a composite growth factor system that combines multiple growth factors (BMPs, IGF-1, TGF-β1, insulin, transferrin, selenium, L-ascorbic acid) in defined ratios. This composite approach creates a synergistic effect where the combination of factors at lower doses achieves superior osteogenic outcomes compared to high-dose single-factor treatment, while minimizing side effects such as heterotopic ossification and inflammation.
3Productivity
If standard cell culture methods are used to expand mesenchymal stem cells, then cell numbers are increased, but the cells fail to integrate with host tissue and form uncontrolled tissue
Solution Approach 1:
The patent applies preliminary action by pre-treating mesenchymal stem cells with a defined serum-free media containing specific growth factors (BMP-2, BMP-4, BMP-6, BMP-7, IGF-1, TGF-β1, insulin, transferrin, selenium, L-ascorbic acid) before implantation. This pre-conditioning primes the cells for controlled differentiation and host tissue integration, ensuring that when the cells are transplanted, they form organized, integrated tissue rather than uncontrolled growth.
Solution Approach 2:
The patent changes the culture conditions from standard serum-based media to a chemically defined serum-free media with specific growth factor concentrations. This parameter change during the expansion phase programs the cells with appropriate differentiation potential and surface characteristics that facilitate controlled integration with host tissue, preventing uncontrolled tissue formation while maintaining high cell yields.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the performance of implanted cells, leads to robust and controlled cartilage and bone formation, improving treatment outcomes for bone, cartilage, and joint disorders by leveraging the body's natural healing processes and maintaining cell viability and differentiation.
Implementation Method 1
the presence of growth factors, hormones and cytokines in the serum may interfere with the effect of the BMP
Implementation Method 2
GDF5 or TGFβ
Implementation Method 3
under conditions allowing the aggregation of cells
Data Source
Figure 1A
Figure 1B~1C
Figure 1D
AI summary
The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells (ATMPs) and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.